Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer

Trial Profile

Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs GSK 2256098 (Primary) ; Trametinib (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 20 Jan 2018 Results assessing safety and efficacy presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top